NCT03044665.

Trial name or title	RAndomized Comparison of efficacy and safety of lipid‐lowerING with statin monotherapy versus statin/ezetimibe combination for high‐risk cardiovascular diseases (RACING trial)
Methods	Study design: RCT, open‐label, parallel 2‐arm trial Follow‐up: 3 years follow‐up
Participants	Inclusion Criteria: age 19‐75 years; documented cardiovascular disease, previous myocardial infarction, acute coronary syndrome, coronary revascularisation and other arterial revascularisation procedures, ischaemic stroke, or peripheral artery disease (PAD) Exclusion Criteria: active liver disease or persistent unexplained serum AST or ALT elevation more than 2 times the upper limit of normal range; allergy or hypersensitivity to any statin or ezetimibe; solid organ transplantation recipient; history of any adverse drug reaction requiring discontinuation of statin; pregnant women, women with potential childbearing, or lactating women; life expectancy less than 3 years; inability to follow the patient over the period of 1 year after enrolment, as assessed by the investigator; inability to understand or read the informed content.
Interventions	Rosuvastatin 20 mg/day versus rosuvastatin 10mg/d plus ezetimibe 10 mg/day
Outcomes	Primary: composite of cardiovascular death, major cardiovascular event, nonfatal stroke. Proportion of patients with LDL‐cholesterol less than 70 mg/dL. Secondary: statin discontinuation or dose‐reduction caused by intolerance.
Starting date	February 1, 2017
Contact information	Yang‐Soo Jang; jangys1212@yuhs.ac
Notes	Location: Korea Expected completion date: February 2022.